Clinical trials: Relapsing Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as…
- Trial name
- OzEAN (NCT05335031)
- Testing
- Ozanimod
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- Bristol-Myers Squibb
Relapsing Remitting Multiple Sclerosis
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active…
- Trial name
- OVERLORD-MS (NCT04578639)
- Testing
- Rituximab, Ocrelizumab
- Where
- 12 sites in Norway, Sweden
- Volunteers
- 214 people
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
This is a prospective, monocentric, double blind, placebo controlled, two arm study. Curcumin is derived from the rhizomes of the plant Curcuma longa (common name, turmeric) belonging to the Zingiberaceae family found in South…
- Trial name
- CONTAIN (NCT01514370)
- Testing
- IFN beta 1a 44 mcg TIW, Curcumin
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
The primary objective is to directly estimate brain glutathione concentrations in vivo using H-MRS at 7T before and after initiation of Tecfidera in established multiple sclerosis (MS) patients considering switching therapy or…
- Trial name
- NCT02218879
- Testing
- Tecfidera
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Yale University
Multiple Sclerosis, Relapsing-Remitting
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.
- Trial name
- NCT00276341
- Testing
- EGb 761® (Tanakan®)
- Where
- 30 sites in France
- Volunteers
- 47 people
- Sponsor
- Ipsen
Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS)
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis
- Trial name
- NCT07006805
- Testing
- CABA-201
- Sponsor
- Cabaletta Bio
Multiple Sclerosis
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population.
- Trial name
- NCT01592097
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Southern California
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
- Trial name
- ENABLE (NCT06433752)
- Testing
- No Intervention
- Where
- 111 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,000 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis Relapse
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
The primary objective was to demonstrate the effect of teriflunomide, in comparison to placebo, on frequency of Multiple Sclerosis (MS) relapses in patients with relapsing forms of MS who are treated with Interferon-beta…
- Trial name
- TERACLES (NCT01252355)
- Testing
- Teriflunomide, Interferon-beta (IFN-beta)
- Where
- 185 sites in United States, Argentina and 26 more
- Volunteers
- 534 people
- Sponsor
- Sanofi
Multiple Sclerosis
VALIDATE: Factor VIII Trending for MS Relapse
Multiple sclerosis (MS) patients hospitalized with an acute motor or visual relapse will be consented. Factor VIII-related labs will be systematically drawn for six months.
- Trial name
- NCT04082468
- Testing
- Blood sample collection for coagulation profile
- Where
- United States
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Relapsing Remitting Multiple Sclerosis
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.
- Trial name
- FILYRA (NCT06949956)
- Volunteers
- 140 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Relapsing Remitting Multiple Sclerosis (RRMS)
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS).
- Trial name
- BEACON (NCT00787657)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 36 sites in Argentina, Bahrain and 34 more
- Volunteers
- 1,723 people
- Sponsor
- Bayer
Progressive Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs and the…
- Trial name
- VASOSEP (NCT02580669)
- Testing
- Neuropsychological assessment, Neurologic consultation, MRIs (with vasoreactivity testing)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Relapsing-remitting Multiple Sclerosis
COMparison Between All immunoTherapies for Multiple Sclerosis.
The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based…
- Trial name
- COMBAT-MS (NCT03193866)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 3,526 people
- Sponsor
- Karolinska Institutet
Relapsing Remitting Multiple Sclerosis (RRMS)
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
The primary objective is to determine adherence to Rebif® New Formulation administered by RebiSmart during 12 weeks of therapy in patients with RRMS.
- Trial name
- SCANSMART (NCT01125475)
- Testing
- RebiSmart
- Where
- Norway
- Volunteers
- 61 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS) - Relapsing-remitting
Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)
This phase of the project aims to analyze the interaction between physical exercise and the phases of the menstrual cycle, evaluating its impact on fatigue, functional capacity, and exercise perception in women with and without…
- Trial name
- ADVICE Phase 1 (NCT06925022)
- Testing
- Strength training session during Early Follicular Phase, Strength Training Protocol during Late Follicular Phase, Strength Training during Mid-Luteal Phase
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidad de Almeria
Relapsing Remitting Multiple Sclerosis
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved by de FDA/EMA in a treatment regimen of 4-weekly 300mg natalizumab infusions.
- Trial name
- SUPERNEXT (NCT04225312)
- Testing
- Personalized extended interval dosing of natalizumab, Standard interval dosing
- Where
- 24 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Amsterdam UMC, location VUmc
Relapsing Remitting Multiple Sclerosis
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab.
- Trial name
- TOPAZ (NCT02255656)
- Testing
- alemtuzumab GZ402673
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 1,062 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi